Triple-negative breast cancer (TNBC) is characterized by negative expression of the hormone receptors [i.e., estrogen receptor (ER) and progesterone receptor (PR)] and the human epidermal growth factor receptor 2 (HER2), accounting for about 10–20% of all breast cancer cases. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.